Cariprazine (Chengdu Kanghong) vs Cariprazine (Vraylar)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline

Cariprazine (Chengdu Kanghong)

Developed by Chengdu Kanghong Pharmaceutical

Phase 3 in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Cariprazine (Vraylar)

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT01104766 · Phase 3 · completed

The trial randomized 617 participants to cariprazine 3 mg, cariprazine 6 mg, aripiprazole 10 mg, or placebo, with participants, investigators, and outcome assessors masked. The prespecified clinical primary endpoint, change in PANSS total score at week 6, was significantly improved with both cariprazine doses versus placebo (p=0.0044 and p<0.0001), supporting a strong evidence grade.

Next expected readout: December 2026 · NCT03817502 (registry estimate)

Reported efficacy

Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4) (met)

Result source: NCT01104766

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCariprazine (Chengdu Kanghong)Cariprazine (Vraylar)
PANSS total, change—Trial running · NCT06589817-23 vs -14.3−8.7 vs placebo6.0mg · wk 6 · n 154NCT01104766
9 other results
  • -14 vs -9.5 9mg · wk 6 · n 36 · Phase 2/3 · primary NCT01625000
  • -13.8 vs -9.5 6mg · wk 6 · n 80 · Phase 2/3 · primary NCT01625000
  • -20.2 vs -14.3 3.0 mg · wk 6 · n 151 · Phase 3 · primary NCT01104766
  • -10.4 vs -9.5 3mg · wk 6 · n 78 · Phase 2/3 · primary NCT01625000
  • -22.8 vs -16 3-6 mg/Day · wk 6 · n 147 · Phase 3 · primary NCT01104779
  • -25.9 vs -16 6-9 mg/Day · wk 6 · n 147 · Phase 3 · primary NCT01104779
  • -17.3 vs -9.5 1.5 mg · wk 6 · n 140 · Phase 2 · primary NCT00694707
  • -20.2 vs -9.5 4.5 mg · wk 6 · n 145 · Phase 2 · primary NCT00694707
  • -18.7 vs -9.5 3.0 mg · wk 6 · n 140 · Phase 2 · primary NCT00694707
CGI-S, change—Trial running · NCT06589817-1.5 vs -1−0.5 vs placebo6.0mg · wk 6 · n 154NCT01104766
9 other results
  • -0.7 vs -0.6 9mg · wk 6 · n 36 · Phase 2/3 · secondary NCT01625000
  • -0.8 vs -0.6 6mg · wk 6 · n 80 · Phase 2/3 · secondary NCT01625000
  • -1.4 vs -1 3.0 mg · wk 6 · n 151 · Phase 3 · secondary NCT01104766
  • -0.7 vs -0.6 3mg · wk 6 · n 78 · Phase 2/3 · secondary NCT01625000
  • -1.4 vs -1 3-6 mg/Day · wk 6 · n 147 · Phase 3 · secondary NCT01104779
  • -1.6 vs -1 6-9 mg/Day · wk 6 · n 147 · Phase 3 · secondary NCT01104779
  • -0.9 vs -0.6 1.5 mg · wk 6 · n 140 · Phase 2 · secondary NCT00694707
  • -1.2 vs -0.6 4.5 mg · wk 6 · n 145 · Phase 2 · secondary NCT00694707
  • -1.1 vs -0.6 3.0 mg · wk 6 · n 140 · Phase 2 · secondary NCT00694707
PANSS response—Trial running · NCT06589817—Not posted · NCT04578756
PSP, change—Trial running · NCT06589817—Not posted · NCT04578756
Relapse (% of patients)—Trial running · NCT06589817—Not posted · NCT04578756

PANSS total, change

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
Cariprazine (Vraylar)
-23 vs -14.3−8.7 vs placebo6.0mg · wk 6 · n 154NCT01104766
9 other results
  • -14 vs -9.5 9mg · wk 6 · n 36 · Phase 2/3 · primary NCT01625000
  • -13.8 vs -9.5 6mg · wk 6 · n 80 · Phase 2/3 · primary NCT01625000
  • -20.2 vs -14.3 3.0 mg · wk 6 · n 151 · Phase 3 · primary NCT01104766
  • -10.4 vs -9.5 3mg · wk 6 · n 78 · Phase 2/3 · primary NCT01625000
  • -22.8 vs -16 3-6 mg/Day · wk 6 · n 147 · Phase 3 · primary NCT01104779
  • -25.9 vs -16 6-9 mg/Day · wk 6 · n 147 · Phase 3 · primary NCT01104779
  • -17.3 vs -9.5 1.5 mg · wk 6 · n 140 · Phase 2 · primary NCT00694707
  • -20.2 vs -9.5 4.5 mg · wk 6 · n 145 · Phase 2 · primary NCT00694707
  • -18.7 vs -9.5 3.0 mg · wk 6 · n 140 · Phase 2 · primary NCT00694707

CGI-S, change

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
Cariprazine (Vraylar)
-1.5 vs -1−0.5 vs placebo6.0mg · wk 6 · n 154NCT01104766
9 other results
  • -0.7 vs -0.6 9mg · wk 6 · n 36 · Phase 2/3 · secondary NCT01625000
  • -0.8 vs -0.6 6mg · wk 6 · n 80 · Phase 2/3 · secondary NCT01625000
  • -1.4 vs -1 3.0 mg · wk 6 · n 151 · Phase 3 · secondary NCT01104766
  • -0.7 vs -0.6 3mg · wk 6 · n 78 · Phase 2/3 · secondary NCT01625000
  • -1.4 vs -1 3-6 mg/Day · wk 6 · n 147 · Phase 3 · secondary NCT01104779
  • -1.6 vs -1 6-9 mg/Day · wk 6 · n 147 · Phase 3 · secondary NCT01104779
  • -0.9 vs -0.6 1.5 mg · wk 6 · n 140 · Phase 2 · secondary NCT00694707
  • -1.2 vs -0.6 4.5 mg · wk 6 · n 145 · Phase 2 · secondary NCT00694707
  • -1.1 vs -0.6 3.0 mg · wk 6 · n 140 · Phase 2 · secondary NCT00694707

PANSS response

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
Cariprazine (Vraylar)
—Not posted · NCT04578756

PSP, change

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
Cariprazine (Vraylar)
—Not posted · NCT04578756

Relapse (% of patients)

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
Cariprazine (Vraylar)
—Not posted · NCT04578756
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Cariprazine (Chengdu Kanghong): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cariprazine (Chengdu Kanghong): 0 of 4 rows · Cariprazine (Vraylar): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCariprazine (Vraylar)
Dropout rate
38.2%6.0mga
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 23 more results
32.9%3.0 mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
36.4%3-6 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
41.9%6-9 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
—
NCT01412060 · Phase 3 · registry result, not featured evidence
69.9%
NCT01104792 · Phase 3 · registry result, not featured evidence
41.4%9mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
60.6%6mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
64.2%3mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
49.3%9mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
39.1%6mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
41.3%3mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
62.7%1.5-9mg
NCT01625897 · Phase 2/3 · registry result, not featured evidence
28.6%1.5-9 mg
NCT01626885 · Phase 2/3 · registry result, not featured evidence
36.4%9 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
50%6 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
18.2%3 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
50.5%
NCT00839852 · Phase 2 · registry result, not featured evidence
10%6 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
25%3 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
25%12.5 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
37.9%1.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
33.8%4.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
34.7%3.0 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
12.7%6.0mga
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 23 more results
9.7%3.0 mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.3%3-6 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
8.8%6-9 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
—
NCT01412060 · Phase 3 · registry result, not featured evidence
10.2%
NCT01104792 · Phase 3 · registry result, not featured evidence
13.8%9mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
25.7%6mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
24.7%3mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
16.4%9mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
14.3%6mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
11.9%3mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
32.5%1.5-9mg
NCT01625897 · Phase 2/3 · registry result, not featured evidence
19%1.5-9 mg
NCT01626885 · Phase 2/3 · registry result, not featured evidence
18.2%9 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
18.8%6 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
9.1%3 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
10.8%
NCT00839852 · Phase 2 · registry result, not featured evidence
10%6 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
16.7%3 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
8.3%12.5 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
9.7%1.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
8.1%4.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
5.4%3.0 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
Serious AEs
4.5%6.0mga
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 23 more results
2.6%3.0 mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
5.4%3-6 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
2.4%6-9 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
13.9%
NCT01412060 · Phase 3 · registry result, not featured evidence
10.1%
NCT01104792 · Phase 3 · registry result, not featured evidence
24.1%9mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
30.3%6mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
17.3%3mg
NCT01626872 · Phase 2/3 · registry result, not featured evidence
6%9mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
12%6mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
9.5%3mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
15.7%1.5-9mg
NCT01625897 · Phase 2/3 · registry result, not featured evidence
4.8%1.5-9 mg
NCT01626885 · Phase 2/3 · registry result, not featured evidence
0%9 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
12.5%6 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
0%3 mg
NCT01626859 · Phase 2/3 · registry result, not featured evidence
12.9%
NCT00839852 · Phase 2 · registry result, not featured evidence
10%6 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
25%3 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
16.7%12.5 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
3.4%1.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
2.7%4.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
0%3.0 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
6.0mga
akathisia 15.3% (placebo 5.9%)
insomnia 14% (placebo 16.3%)
headache 10.2% (placebo 11.1%)
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 23 more results
3.0 mg
insomnia 13.5% (placebo 16.3%)
akathisia 7.7% (placebo 5.9%)
anxiety 7.7% (placebo 7.2%)
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
3-6 mg/Day
akathisia 15.9% (placebo 3.4%)
constipation 9.3% (placebo 3.4%)
headache 9.3% (placebo 12.9%)
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
6-9 mg/Day
akathisia 16.9% (placebo 3.4%)
headache 16.2% (placebo 12.9%)
insomnia 10.8% (placebo 10.9%)
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
headache 7.9% (placebo 7.1%)
insomnia 7.9% (placebo 8.1%)
nasopharyngitis 7.9% (placebo 5.1%)
NCT01412060 · Phase 3 · registry result, not featured evidence
akathisia 20.1%
headache 17.7%
insomnia 17.7%
NCT01104792 · Phase 3 · registry result, not featured evidence
9mg
nasopharyngitis 22.4%
schizophrenia 19%
insomnia 13.8%
NCT01626872 · Phase 2/3 · registry result, not featured evidence
6mg
akathisia 13.8%
nasopharyngitis 11.9%
insomnia 11%
NCT01626872 · Phase 2/3 · registry result, not featured evidence
3mg
nasopharyngitis 25.9%
akathisia 18.5%
schizophrenia 14.8%
NCT01626872 · Phase 2/3 · registry result, not featured evidence
9mg
schizophrenia 19.4% (placebo 18.3%)
constipation 17.9% (placebo 11.9%)
extrapyramidal disorder 16.4% (placebo 9.5%)
NCT01625000 · Phase 2/3 · registry result, not featured evidence
6mg
constipation 15% (placebo 11.9%)
akathisia 14.3% (placebo 7.9%)
extrapyramidal disorder 14.3% (placebo 9.5%)
NCT01625000 · Phase 2/3 · registry result, not featured evidence
3mg
akathisia 22.2% (placebo 7.9%)
constipation 16.7% (placebo 11.9%)
headache 15.1% (placebo 11.1%)
NCT01625000 · Phase 2/3 · registry result, not featured evidence
1.5-9mg
schizophrenia 33.7%
nasopharyngitis 31.3%
nausea 18.1%
NCT01625897 · Phase 2/3 · registry result, not featured evidence
1.5-9 mg
nasopharyngitis 42.9%
schizophrenia 19%
headache 16.7%
NCT01626885 · Phase 2/3 · registry result, not featured evidence
9 mg
akathisia 27.3%
insomnia 27.3%
restlessness 18.2%
NCT01626859 · Phase 2/3 · registry result, not featured evidence
6 mg
nasopharyngitis 37.5%
schizophrenia 31.3%
insomnia 25%
NCT01626859 · Phase 2/3 · registry result, not featured evidence
3 mg
restlessness 54.5%
akathisia 45.5%
nasopharyngitis 27.3%
NCT01626859 · Phase 2/3 · registry result, not featured evidence
akathisia 14%
insomnia 14%
weight increased 11.8%
NCT00839852 · Phase 2 · registry result, not featured evidence
6 mg
insomnia 30%
nasopharyngitis 30%
toothache 20%
NCT00862992 · Phase 2 · registry result, not featured evidence
3 mg
insomnia 33.3%
diarrhoea 16.7%
nasopharyngitis 16.7%
NCT00862992 · Phase 2 · registry result, not featured evidence
12.5 mg
akathisia 25%
alanine aminotransferase increased 25%
blood creatine phosphokinase increased 25%
NCT00862992 · Phase 2 · registry result, not featured evidence
1.5 mg
extrapyramidal disorder 11.7% (placebo 6%)
headache 11.7% (placebo 11.3%)
insomnia 10.3% (placebo 7.3%)
NCT00694707 · Phase 2 · registry result, not featured evidence
4.5 mg
insomnia 16.3% (placebo 7.3%)
extrapyramidal disorder 12.9% (placebo 6%)
akathisia 8.8% (placebo 5.3%)
NCT00694707 · Phase 2 · registry result, not featured evidence
3.0 mg
insomnia 16.4% (placebo 7.3%)
akathisia 9.6% (placebo 5.3%)
extrapyramidal disorder 9.6% (placebo 6%)
NCT00694707 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 20 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cariprazine (Vraylar)

PANSS Total -17.3 vs -9.5 placebo score @ 6wk1.5 mg
absolute change · score
NCT00694707 · Phase 2 · registry result, not featured evidence
show 9 more results
-14 vs -9.5 placebo score @ 6wk9mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
-23 vs -14.3 placebo score @ 6wk6.0mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
-13.8 vs -9.5 placebo score @ 6wk6mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
-20.2 vs -9.5 placebo score @ 6wk4.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
-20.2 vs -14.3 placebo score @ 6wk3.0 mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
-10.4 vs -9.5 placebo score @ 6wk3mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
-18.7 vs -9.5 placebo score @ 6wk3.0 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
-22.8 vs -16 placebo score @ 6wk3-6 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
-25.9 vs -16 placebo score @ 6wk6-9 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.9 vs -0.6 placebo score @ 6wk1.5 mg
absolute change · score
NCT00694707 · Phase 2 · registry result, not featured evidence
show 9 more results
-0.7 vs -0.6 placebo score @ 6wk9mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
-1.5 vs -1 placebo score @ 6wk6.0mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.8 vs -0.6 placebo score @ 6wk6mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
-1.2 vs -0.6 placebo score @ 6wk4.5 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
-1.4 vs -1 placebo score @ 6wk3.0 mg
NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.7 vs -0.6 placebo score @ 6wk3mg
NCT01625000 · Phase 2/3 · registry result, not featured evidence
-1.1 vs -0.6 placebo score @ 6wk3.0 mg
NCT00694707 · Phase 2 · registry result, not featured evidence
-1.4 vs -1 placebo score @ 6wk3-6 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.6 vs -1 placebo score @ 6wk6-9 mg/Day
NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3
Time to First Relapse 7.36 vs 3.02 placebo months
time to event · months
NCT01412060 · Phase 3 · registry result, not featured evidence · converted to months from 224 days as posted
PANSS Total -5 score @ 48wk
absolute change · score
No placebo or comparator arm
Change From Baseline
NCT01104792 · Phase 3 · registry result, not featured evidence
CGI-S -0.1 score @ 48wk
absolute change · score
No placebo or comparator arm
Change From Baseline
NCT01104792 · Phase 3 · registry result, not featured evidence
PANSS Total -0.6 score @ 2wk6 mg
absolute change · score
No placebo or comparator arm
NCT00862992 · Phase 2 · registry result, not featured evidence
show 3 more results
-0.2 score @ 2wk3 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
-3.9 score @ 2wk12.5 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
-38.5 score @ 48wk
NCT00839852 · Phase 2 · registry result, not featured evidence
CGI-S -0.1 score @ 2wk6 mg
absolute change · score
No placebo or comparator arm
NCT00862992 · Phase 2 · registry result, not featured evidence
show 3 more results
0.3 score @ 2wk3 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
-0.1 score @ 2wk12.5 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
-2 score @ 48wk
NCT00839852 · Phase 2 · registry result, not featured evidence
CGI-I 3.7 score @ 2wk6 mg
absolute value · score
No placebo or comparator arm
NCT00862992 · Phase 2 · registry result, not featured evidence
show 2 more results
4.1 score @ 2wk3 mg
NCT00862992 · Phase 2 · registry result, not featured evidence
3.8 score @ 2wk12.5 mg
NCT00862992 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine (Chengdu Kanghong)'s landscape · Cariprazine (Vraylar)'s landscape